Research and Clinical Trials

Title  

Janssen 63935937MDS3001: A Study to Evaluate Imetelstat (JNJ63935937) in Transfision-DependentSubjects with IPSS Low or Intermediate-I Risk Myelodysplastic Syndrom (MDS) that is Relapsed/ Refractory to Erythropoiesis-Stemulating Agent (ESA) Treatment

Brief Description  

Primary Part I: Evaluate efficacy and safety of imetelstat in transfusion dependent subjects with low/ intermediate-I risk MDS that is relapsed/ refratory to ESA treatment. Part I: To compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat to placebo in tranfusion dependent subjects with low or intermediate-I risk MDS that is relapsed/ refractory to ESA treatment.

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Myeloid and Monocytic Leukemia

Status  

OPEN

Start Date  

04/18/2016

IRB Number  

00016752

Principal Investigator  

Grunwald, Michael Richard

Contact Name  

Mallory Tucker

For More Information, Contact  Mallory  , Tucker
Phone:  980-442-2011 Fax:    
Email:  Mallory.Rodgers@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204